| abstract |
The invention relates to a pharmaceutical combination for the prevention and/or treatment of multiple sclerosis, containing the first active ingredient, which is (R)-5-[3-chloro-4-(2,3-dihydroxypropoxy)benz[Z]ylidene]-2- ([Z]-propylimino)-3-o-tolylthiazolidin-4-one or a pharmaceutically acceptable salt thereof, and a second active ingredient selected from the group consisting of monomethyl fumarate and dimethyl fumarate or a pharmaceutically acceptable salt thereof. |